Happy New Year!
It is that time of the year again when we take the time to look back and review the previous year. Probably the most striking thing I see is the sheer volume of articles published in the field of reproductive psychiatry.
This means that it has been a great year for our website as well, with over 1.2 million visits. Thanks to all of our readers!
Ruta Nonacs, MD PhD
Looking at the stats, these were the most popular posts on our site in 2016:
I would also like to take this opportunity to highlight some of the most important issues in 2016:
We continue to move forward with screening for depression in all pregnant and postpartum women; however, we continue to struggle in terms of ensuring that we can provide consistent access to specialized care for women with perinatal mood and anxiety disorders.
Many studies have explored novel strategies in order to reach and provide care to women with perinatal mood and anxiety disorders:
Atypical antipsychotic medications are now commonly used to treat a spectrum of psychiatric disorders. We are finally getting more data on the reproductive safety of these medications, and the data has been reassuring.
When we discuss the treatment of depression during pregnancy, we must weigh the possible risks associated with medication exposure against the risk of untreated depression in the mother. We continue to see more studies documenting the negative effects of maternal depression on pregnancy and the developing fetus.
And there has been at least one study indicating that treatment with medication may actually decrease the risk of adverse outcomes in women with depression during pregnancy:
More states have legalized marijuana. We are seeing more and more women using marijuana on a regular basis who are either pregnant and planning to conceive, despite limited information regarding the reproductive safety of this drug.
We have heard about the opioid epidemic in the United States. The problem has now trickled down to infants and children.